Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19170240 | METABOLICALLY OPTIMIZED CELL CULTURE | April 2025 | October 2025 | Allow | 6 | 0 | 0 | No | No |
| 18223164 | EXTRACELLULAR MATRIX SUBSTITUTE IN A CELLULAR MICROCOMPARTMENT | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18256530 | CELL LINES FOR PRODUCTION OF ADENO-ASSOCIATED VIRUS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18325648 | METHODS OF TREATING CANCER | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18038190 | METHODS AND COMPOSITIONS FOR LINKING RNA STEM LOOPS | May 2023 | October 2025 | Allow | 29 | 0 | 0 | No | No |
| 18250158 | ANTI-APOPTOTIC VECTOR AND METHOD OF USING THE SAME | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18301228 | CONJUGATE SYSTEMS AND METHODS OF USE THEREOF | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18030683 | RECOMBINANT ADENO-ASSOCIATED VIRUSES FOR CNS OR MUSCLE DELIVERY | April 2023 | October 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18194551 | METHOD OF GENERATING MULTIPOTENT STEM CELLS | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18116415 | METHOD FOR PRODUCING OLIGODENDROCYTE-LIKE CELLS | March 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18177695 | UNIVERSAL DONOR CELLS | March 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18177693 | UNIVERSAL DONOR CELLS | March 2023 | November 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18043108 | METHOD, SYSTEM AND DEVICE FOR PROGRAMMED CELL FREEZING | February 2023 | September 2025 | Allow | 30 | 0 | 0 | No | No |
| 18067204 | ENCAPSULATED CELLS EXPRESSING IL-12 AND USES THEREOF | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 17906679 | CARDIAC ORGANOID, MANUFACTURING METHOD THEREFOR, AND METHOD FOR EVALUATING DRUG TOXICITY BY USING SAME | September 2022 | August 2025 | Allow | 35 | 0 | 0 | No | No |
| 17905830 | IN-VITRO TRANSCRIPT MRNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17897011 | AGENT FOR CRYOPRESERVATION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA USING THE SAME | August 2022 | August 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17796839 | Compositions and Methods for Controlling Production of Polypeptides in Cells | August 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17861042 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | July 2022 | July 2025 | Allow | 36 | 1 | 1 | No | No |
| 17791096 | COMPOSITION FOR REINFORCING FUNCTION OF STEM CELL | July 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17845793 | Chimeric Antigen Receptor and Natural Killer Cells Expressing Same | June 2022 | June 2025 | Allow | 35 | 3 | 1 | No | No |
| 17843121 | METABOLICALLY OPTIMIZED CELL CULTURE | June 2022 | December 2024 | Allow | 30 | 1 | 0 | No | No |
| 17757041 | METHODS AND CONSTRUCTS FOR TRANSIENT PRODUCTION OF LENTIVIRAL VECTOR | June 2022 | April 2025 | Allow | 34 | 1 | 0 | No | No |
| 17778309 | PROCESSES FOR THE PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) AND METHODS OF USING THE SAME | May 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17776506 | Methods for Reprogramming Cells | May 2022 | October 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17755051 | FIBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING CHOLANGITIS | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17754812 | PREVENTION OF RECURRENT MISCARRIAGES THROUGH ADMINISTRATION OF FIBROBLASTS AND FIBROBLAST-EDUCATED PATERNAL CELLS | April 2022 | May 2025 | Allow | 37 | 0 | 0 | No | No |
| 17767777 | METHODS AND COMPOSITIONS FOR PRIME EDITING RNA | April 2022 | June 2025 | Allow | 38 | 0 | 0 | No | No |
| 17715177 | Genome Engineering | April 2022 | July 2025 | Allow | 39 | 6 | 1 | No | No |
| 17765637 | METHOD FOR PRODUCING FIBRIN SHEET | March 2022 | April 2025 | Allow | 37 | 0 | 0 | No | No |
| 17707060 | Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17703750 | Animal models and therapeutic molecules | March 2022 | October 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17701267 | INDUCED PLURIPOTENT CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF MYELIN DISORDERS | March 2022 | March 2025 | Allow | 35 | 1 | 1 | No | No |
| 17651505 | METHOD TO PREPARE SPERM | February 2022 | March 2025 | Allow | 37 | 1 | 0 | No | No |
| 17597743 | HEXOKINASE 1 ISOFORM B FOR USE AS A PROGNOSIS MARKER AND SPECIFIC TARGET AGAINST CANCER | January 2022 | August 2025 | Allow | 42 | 0 | 1 | No | No |
| 17531172 | UNIVERSAL DONOR CELLS | November 2021 | March 2025 | Allow | 40 | 3 | 1 | No | No |
| 17434209 | IMPROVED PROCESS FOR DNA INTEGRATION USING RNA-GUIDED ENDONUCLEASES | August 2021 | March 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17407558 | Use of Lyso-GB1 as Druggable Target | August 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17373194 | ENGINEERED LYMPHOCYTE COMPOSITIONS, METHODS AND SYSTEMS | July 2021 | November 2025 | Abandon | 53 | 1 | 0 | No | No |
| 17363798 | Systems and Methods for the Production of Human Polyclonal Antibodies | June 2021 | August 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17356423 | ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS | June 2021 | July 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17356411 | ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS | June 2021 | July 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17304585 | METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND USES THEREOF | June 2021 | August 2025 | Allow | 50 | 1 | 1 | No | No |
| 17331423 | Coordinating Gene Expression Using RNA Destabilizing Elements | May 2021 | September 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17282421 | RAAV Vectors for the Treatment of GM1 and GM2 Gangliosidosis | April 2021 | June 2025 | Allow | 50 | 2 | 1 | No | No |
| 17200633 | GENERATION OF SYNTHETIC GENOMES | March 2021 | December 2024 | Allow | 45 | 1 | 1 | No | No |
| 17189434 | MANUFACTURING METHOD FOR SUBSTRATE ON WHICH NERVE CELLS ARE ARRANGED | March 2021 | December 2024 | Allow | 46 | 4 | 0 | Yes | No |
| 17269787 | METHODS AND COMPOSITIONS FOR RNA EXPRESSION OF MYC INHIBITORS | February 2021 | January 2025 | Abandon | 47 | 0 | 1 | No | No |
| 16973688 | Compositions for Drug Delivery and Methods of Use Thereof | December 2020 | March 2025 | Allow | 51 | 1 | 1 | No | No |
| 17096192 | CHIMERIC ANTIGEN RECEPTOR AND ITS USE | November 2020 | May 2025 | Allow | 54 | 2 | 1 | No | No |
| 17075556 | VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B | October 2020 | August 2025 | Abandon | 58 | 3 | 1 | No | No |
| 17025637 | SPHERICAL NUCLEIC ACIDS WITH TAILORED AND ACTIVE PROTEIN CORONAE | September 2020 | January 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 16970790 | T CELL DISEASE TREATMENT TARGETING TAG-72 | August 2020 | December 2024 | Allow | 52 | 2 | 1 | No | No |
| 16970937 | METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND USES THEREOF | August 2020 | April 2025 | Allow | 56 | 3 | 1 | No | No |
| 16835913 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION | March 2020 | February 2025 | Allow | 59 | 4 | 0 | Yes | No |
| 16836513 | Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations | March 2020 | June 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16635863 | CELLULAR MODELS OF AND THERAPIES FOR OCULAR DISEASES | January 2020 | April 2025 | Allow | 60 | 3 | 2 | Yes | No |
| 16086127 | Trans-Replicating RNA | September 2018 | February 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 10568572 | HYDROGEN SUCCINATE SALTS OF [TRANS-4-((1R,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT | August 2006 | March 2010 | Allow | 49 | 2 | 0 | No | Yes |
| 10519722 | AMIDE DERIVATIVE | December 2004 | October 2008 | Allow | 46 | 4 | 0 | No | No |
| 10874992 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | June 2004 | October 2007 | Allow | 40 | 1 | 0 | Yes | No |
| 10701584 | SYNTHETIC LACTONE FORMULATIONS AND METHOD OF USE | November 2003 | August 2007 | Allow | 46 | 2 | 1 | No | Yes |
| 10476196 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | October 2003 | December 2006 | Allow | 38 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIBUYA, MARK LANCE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SHIBUYA, MARK LANCE works in Art Unit 1631 and has examined 28 patent applications in our dataset. With an allowance rate of 82.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 50 months.
Examiner SHIBUYA, MARK LANCE's allowance rate of 82.1% places them in the 54% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SHIBUYA, MARK LANCE receive 2.07 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SHIBUYA, MARK LANCE is 50 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.8% benefit to allowance rate for applications examined by SHIBUYA, MARK LANCE. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.5% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 87.5% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 10.7% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.7% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.